Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
Jpn J Ophthalmol. 2023 Nov;67(6):658-667. doi: 10.1007/s10384-023-01020-8. Epub 2023 Aug 19.
To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma.
Retrospective observational cohort study.
A retrospective observational cohort study using JMDC Claims Database. Patients aged 20 years or older diagnosed with glaucoma between February 1, 2017, and March 31, 2020, and prescribed CAR/LAT or another BB/FP were included.
A total of 16,612 patients (7423 in the CAR/LAT group and 9189 in the other BB/FP group) were included. The cumulative treatment persistence rate at the end of follow-up was 42.0% (64.9% at 1 year, 53.4% at 2 years, 45.0% at 3 years, and 42.0% at 4 years) in the CAR/LAT group and 34.7% (54.8% at 1 year, 43.6% at 2 years, 37.1% at 3 years, and 34.7% at 4 years) in the other BB/FP group. Treatment persistence was significantly longer in the CAR/LAT group compared to that in the other BB/FP group (hazard ratio 0.747, p < 0.0001). Over the treatment period, the number of patients who discontinued treatment was 3281 (44.2%) in the CAR/LAT group and 4926 (53.6%) in the other BB/FP group; the median duration of treatment was 135 days and 97 days, respectively.
The study results suggest that persistence rates vary depending on the BB/FP and CAR/LAT appears to be more persistent than other BB/FP.
调查卡替洛尔盐酸盐/拉坦前列素固定剂量组合滴眼液（CAR/LAT）和其他β-阻滞剂/前列腺素 FP 受体激动剂固定剂量组合滴眼液（BB/FP）在治疗青光眼方面的治疗持久性。
回顾性观察队列研究。
使用 JMDC 索赔数据库进行回顾性观察队列研究。纳入 2017 年 2 月 1 日至 2020 年 3 月 31 日期间被诊断为青光眼且年龄在 20 岁或以上、并接受 CAR/LAT 或其他 BB/FP 治疗的患者。
共纳入 16612 名患者（CAR/LAT 组 7423 名，其他 BB/FP 组 9189 名）。CAR/LAT 组的累积治疗随访结束时的治疗持续率为 42.0%（1 年时为 64.9%，2 年时为 53.4%，3 年时为 45.0%，4 年时为 42.0%），其他 BB/FP 组为 34.7%（1 年时为 54.8%，2 年时为 43.6%，3 年时为 37.1%，4 年时为 34.7%）。CAR/LAT 组的治疗持续时间明显长于其他 BB/FP 组（风险比 0.747，p<0.0001）。在治疗期间，CAR/LAT 组有 3281 名（44.2%）患者停止治疗，其他 BB/FP 组有 4926 名（53.6%）患者停止治疗；CAR/LAT 组和其他 BB/FP 组的中位治疗持续时间分别为 135 天和 97 天。
研究结果表明，治疗持久性因 BB/FP 而异，CAR/LAT 似乎比其他 BB/FP 更持久。
